慢性冠脉综合征患者PCI围术期心梗的发生率与结局
本研究基于Bern PCI注册研究,纳入2010至2018年4404例接受PCI的慢性冠脉综合征患者,比较第三版和第四版通用心梗定义、ARC-2及SCAI标准下围术期心梗的发生率及对1年心源性死亡的预测价值。结果显示ARC-2和SCAI定义的发生率远低于通用定义,但对1年心源性死亡的预后区分能力更强。
要点
- 第三版和第四版UDMI定义的围术期心梗发生率分别为18.0%和14.9%,ARC-2和SCAI均为2.0%。
- SCAI定义围术期心梗患者1年心源性死亡率为10.0%,ARC-2为5.8%,UDMI为2.9%-3.0%。
- ARC-2和SCAI定义对1年心源性死亡的预后价值优于第三版和第四版UDMI。
核心结论
- 在慢性冠脉综合征PCI患者中,ARC-2和SCAI定义的围术期心梗发生率比第三版和第四版UDMI低7至9倍。
- ARC-2和SCAI定义的围术期心梗对1年心源性死亡的预后价值优于第三版和第四版UDMI。
研究设计与样本
- 基于Bern PCI注册研究(CARDIOBASE Bern PCI Registry;NCT02241291)的回顾性分析。
- 纳入2010至2018年接受PCI的慢性冠脉综合征患者共4404例。
- 依据高敏肌钙蛋白,分别按第三版和第四版通用心梗定义、ARC-2及SCAI标准评估围术期心梗。
- 主要终点为1年心源性死亡。
主要发现
- 第三版UDMI、第四版UDMI、ARC-2和SCAI定义的围术期心梗发生率分别为18.0%、14.9%、2.0%和2.0%。
- 上述定义下围术期心梗患者的1年心源性死亡率分别为2.9%、3.0%、5.8%和10.0%。
- ARC-2定义与1年心源性死亡的HR为3.90(95%CI 1.54-9.93)。
- SCAI定义与1年心源性死亡的HR为7.66(95%CI 3.64-16.11)。
- 第三版UDMI的HR为1.76(95%CI 1.04-3.00),第四版UDMI的HR为1.93(95%CI 1.11-3.37)。
关键数值与推荐
- 围术期心梗定义依据第三版和第四版通用心梗定义、ARC-2及SCAI标准,基于高敏肌钙蛋白。
- 第三版UDMI定义发生率18.0%,第四版UDMI定义发生率14.9%,ARC-2定义发生率2.0%,SCAI定义发生率2.0%。
- ARC-2定义1年心源性死亡HR 3.90(95%CI 1.54-9.93),SCAI定义HR 7.66(95%CI 3.64-16.11)。
- 第三版UDMI定义1年心源性死亡HR 1.76(95%CI 1.04-3.00),第四版UDMI定义HR 1.93(95%CI 1.11-3.37)。
临床怎么用
- 在慢性冠脉综合征PCI患者中评估围术期心梗时,ARC-2和SCAI定义发生率低但对1年心源性死亡预后区分更优。
- 临床研究或质量评价中可优先考虑ARC-2或SCAI标准定义围术期心梗,以识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Definitions of periprocedural myocardial infarction (MI) differ with respect to biomarker threshold as well as ancillary criteria for myocardial ischemia and are limited in terms of validation. OBJECTIVES: This study evaluated the frequency and impact of periprocedural MI by using various MI definitions among patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). METHODS: Between 2010 and 2018, periprocedural MIs were assessed according to the third and fourth Universal Definition of Myocardial Infarction (UDMI), Academic Research Consortium-2 (ARC-2), and Society for Cardiovascular Angiography and Interventions (SCAI) criteria based on high-sensitivity troponin in patients with CCS undergoing PCI enrolled into the Bern PCI registry. The primary endpoint was cardiac death at 1 year. RESULTS: Among 4,404 patients with CCS, periprocedural MI defined by the third UDMI, fourth UDMI, ARC-2, and SCAI were observed in 18.0%, 14.9%, 2.0%, and 2.0% of patients, respectively. Among patients with periprocedural MI defined by the third UDMI, fourth UDMI, ARC-2, and SCAI, cardiac mortality at 1 year was 2.9%, 3.0%, 5.8%, and 10.0%. The ARC-2 (HR: 3.90; 95% CI: 1.54-9.93) and SCAI (HR: 7.66; 95% CI: 3.64-16.11) were more relevant compared with the third UDMI (HR: 1.76; 95% CI: 1.04-3.00) and fourth UDMI (HR: 1.93; 95% CI: 1.11-3.37) for cardiac death at 1 year. CONCLUSIONS: Among patients with CCS undergoing PCI, periprocedural MI defined according to the ARC-2 and SCAI criteria was 7 to 9 times less frequent compared with the third and fourth UDMI. Periprocedural MI defined by using the ARC-2 and SCAI were more prognostic for cardiac death at 1 year compared with the third and fourth UDMI. (CARDIOBASE Bern PCI Registry; NCT02241291).
引用
- Ueki Y, Otsuka T, Bär S, et al. Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI. J Am Coll Cardiol. 2022. PMID: 35144742. doi:10.1016/j.jacc.2021.11.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。